Heidelberg, Germany-based Revier Therapeutics has closed a EUR 6 million seed financing round to advance a preclinical pipeline of selective class IIa histone deacetylase (HDAC) inhibitors targeting cardiometabolic disease, marking the company's public launch after incorporating in 2023.
KHAN Technology Transfer Fund II led the round, with participation from High-Tech Gründerfonds (HTGF), VORNvc, and private investors through Revier Invest Heidelberg. The company said proceeds will fund preclinical development of its two lead programs and build out operational, scientific, and clinical functions. No prior funding rounds have been publicly disclosed; the company operated in stealth from incorporation until this announcement.
Revier's platform is based on research from Prof. Johannes Backs, Director of the Institute of Experimental Cardiology at Heidelberg University and the company's scientific founder, whose laboratory has investigated the role of class IIa HDACs in cardiometabolic disease. Revier is developing orally available small molecules designed to selectively inhibit pathological class IIa HDAC enzymatic activity while preserving their non-enzymatic functions, with the aim of avoiding toxicities associated with less selective pan-HDAC inhibitors.